PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38
|
作者：
Banerjee, Susana [2 ]
Kaye, Stan [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England
来源：
CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期
关键词：
PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;
D O I：
10.1007/s11912-011-0193-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.
引用
收藏
页码：442 / 449
页数：8
相关论文
共 50 条
  • [41] Beyond breast and ovarian cancers: PARP BRCA mutation-associated and BRCA-like inhibitors for solid tumors
    O'Sullivan, Clara C.
    Moon, Dominic H.
    Kohn, Elise C.
    Lee, Jung-Mim
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [42] PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
    Shao, Fengping
    Duan, Yaoyun
    Zhao, Yunhe
    Li, Yinguang
    Liu, Jun
    Zhang, Cai
    He, Shanyang
    AGING-US, 2021, 13 (06): : 8975 - 8988
  • [43] Synthetic lethality of PARP inhibitors and metformin in BRCA1 intact ovarian cancer
    Hijaz, M.
    Chhina, J.
    Dar, S.
    Tebbe, C.
    Al-Wahab, Z.
    Hanna, R. K.
    Rattan, R.
    Munkarah, A. R.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 18 - 18
  • [44] Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
    Wang, Chuanlin
    Gao, Pengning
    Xu, Jiali
    Liu, Shanling
    Tian, Wenda
    Liu, Jiayu
    Zhou, Lan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA
    Grelletyy, T.
    Peyraud, F.
    Sevenet, N.
    Tredan, O.
    Dohollou, N.
    Barouk-Simonet, E.
    Kind, M.
    Longy, M.
    Blay, J. -Y.
    Italiano, A.
    ANNALS OF ONCOLOGY, 2020, 31 (06) : 822 - 823
  • [46] PARP inhibition in BRCA2-mutated prostate cancer
    Nientiedt, C.
    Tolstov, Y.
    Volckmar, A-L
    Endris, V.
    Bonekamp, D.
    Haberkorn, U.
    Jaeger, D.
    Sueltmann, H.
    Stenzinger, A.
    Hohenfellner, M.
    Gruellich, C.
    Duensing, S.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 189 - 191
  • [47] Progress in BRCA-Mutated Ovarian Cancer
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2567 - 2568
  • [48] PARP INHIBITORS IN OVARIAN CANCER THERAPY
    Pisula, Agata
    Sienicka, Agnieszka
    Dobrowolska-Redo, Agnieszka
    Kacperczyk-Bartnik, Joanna
    Romejko-Wolniewicz, Ewa
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
  • [49] PARP Inhibitors in Ovarian Cancer Treatment
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2197 - 2198
  • [50] PARP Inhibitors in Ovarian Cancer: A Review
    David M. O’Malley
    Thomas C. Krivak
    Nashwa Kabil
    Jiefen Munley
    Kathleen N. Moore
    Targeted Oncology, 2023, 18 : 471 - 503
12345